MetaCap

Dyne Therapeutics (DYN) vs Viking Therapeutics (VKTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dyne Therapeutics (DYN) has outperformed Viking Therapeutics (VKTX) over the past year, losing 26.8% versus a loss of 27.7%. Over five years, VKTX leads with a +360.4% price change compared with +5.4% for DYN. Viking Therapeutics is the larger company by market cap ($3.16 billion vs $2.90 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DYN-26.82%VKTX-27.70%
+29%-3%-36%
Nov 21, 20251 yearNov 20, 2026
DYN-1.84%VKTX+339.18%
+1485%+670%-145%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DYN versus VKTX key metrics
MetricDYNVKTX
Share price$15.50$24.77
Market cap$2.90B$3.16B
1-day change-3.31%-4.14%
YTD return-20.76%-29.59%
1-year return-26.82%-27.70%
5-year return+5.37%+360.41%
EPS (TTM)$-3.62$-5.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-446.21M$-359.64M
52-week high$27.31$43.10
52-week low$14.00$23.82
Distance from 52-week high-43.23%-42.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+121.48%+284.82%
Average volume2.94M5.31M
Shares outstanding187.39M127.52M
Employees32274
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

About Viking Therapeutics

VKTX stock →

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

DYN vs VKTX FAQ

Which is bigger, Dyne Therapeutics or Viking Therapeutics?

Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.16B compared with $2.90B for Dyne Therapeutics (DYN).

Which stock has performed better over the past year, DYN or VKTX?

DYN returned -26.82% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.

Are Dyne Therapeutics and Viking Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons